- Home
- DSP vs HRTX Comparison
DSP vs HRTX Comparison
Compare DSP & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- HRTX
- Stock Information
- Founded
- DSP 1999
- HRTX 1983
- Country
- DSP United States
- HRTX United States
- Employees
- DSP N/A
- HRTX N/A
- Industry
- DSP EDP Services
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- HRTX Health Care
- Exchange
- DSP Nasdaq
- HRTX Nasdaq
- Market Cap
- DSP 291.3M
- HRTX 270.7M
- IPO Year
- DSP 2021
- HRTX 1987
- Fundamental
- Price
- DSP $12.34
- HRTX $2.38
- Analyst Decision
- DSP Strong Buy
- HRTX Strong Buy
- Analyst Count
- DSP 7
- HRTX 3
- Target Price
- DSP $23.29
- HRTX $5.67
- AVG Volume (30 Days)
- DSP 653.0K
- HRTX 2.7M
- Earning Date
- DSP 03-03-2025
- HRTX 05-06-2025
- Dividend Yield
- DSP N/A
- HRTX N/A
- EPS Growth
- DSP N/A
- HRTX N/A
- EPS
- DSP 0.14
- HRTX N/A
- Revenue
- DSP $289,235,000.00
- HRTX $144,285,000.00
- Revenue This Year
- DSP $13.31
- HRTX $11.81
- Revenue Next Year
- DSP $16.25
- HRTX $15.79
- P/E Ratio
- DSP $87.00
- HRTX N/A
- Revenue Growth
- DSP 29.74
- HRTX 13.57
- 52 Week Low
- DSP $7.77
- HRTX $1.04
- 52 Week High
- DSP $26.33
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- DSP 27.55
- HRTX 58.92
- Support Level
- DSP $11.62
- HRTX $2.29
- Resistance Level
- DSP $13.77
- HRTX $2.56
- Average True Range (ATR)
- DSP 1.15
- HRTX 0.20
- MACD
- DSP -0.37
- HRTX -0.01
- Stochastic Oscillator
- DSP 7.12
- HRTX 46.43
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.